(908) 425-4878

News

Flemington Photographer Helps Launch Latest iPhone App

Published: Feb 17, 2011 | Last modified: Feb 17, 2011
FLEMINGTON, N.J. (February 17, 2011) - The camera work of Flemington photographer Audrey Kerchner has helped launch one of the newest iPhone Apps to hit the mobile computing industry. "JustYourTrip New York" was launched on Wednesday and features Ker...

NobleStrategy’s Parrish Receives NYU Martin Luther King, Jr. Award

Published: Feb 10, 2011 | Last modified: Feb 10, 2011
NEW YORK and NEWARK, N.J. (February 10, 2011) - William S. Parrish, Jr., President & CEO of NobleStrategy, a construction management and training firm, yesterday was awarded the New York University Martin Luther King, Jr. Faculty Award on the 50th an...

Hance Construction Selects Yankee Public Relations To Build Brand Awareness

Published: Jan 19, 2011 | Last modified: Jan 27, 2011
ALEXANDRIA and WASHINGTON, N.J. (January 19, 2011) - Yankee Public Relations today announced that it has been selected to build brand awareness for Hance Construction, an Authorized Butler Builder® and one of the leading contractors of metal structu...

Octapharma USA Supports Program for The Diagnosis and Management of von Willebrand Disease

Published: Jan 24, 2011 | Last modified: Jan 24, 2011
ALEXANDRIA, Va. and HOBOKEN, N.J. (January 24, 2011) - An unrestricted grant from Octapharma USA supported the development of a Continuing Education (CE) initiative entitled the "The Diagnosis and Management of von Willebrand Disease," a program of t...

Octapharma Targets Primary Immune Deficiency Research with Grant for The Mount Sinai Medical Center

Published: Jan 18, 2011 | Last modified: Jan 18, 2011
NEW YORK and HOBOKEN, NJ (January 18, 2011) - Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma...

Researchers Propose New Objective Criteria for Evaluating the Treatment of von Willebrand Disease

Published: Dec 14, 2010 | Last modified: Dec 14, 2010
HOBOKEN, NJ (December 8, 2010) - Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease (VWD) and reported on their application of these criteria...

FDA Approves octaplex® for Fast Track Development

Published: Dec 1, 2010 | Last modified: Dec 1, 2010
HOBOKEN, NJ (December 1, 2010) - The U.S. Food and Drug Administration (FDA) has approved Octapharma USA's Investigational New Drug Application for octaplex® (Human Prothrombin Complex, Freeze Dried) as a Fast Track Product for "Reversal of Anticoag...

Octapharma Supports VWD Educational Initiatives Launched at Hemophilia Foundation Annual Meeting

Published: Nov 9, 2010 | Last modified: Nov 9, 2010
HOBOKEN, NJ - Octapharma USA is proud to support educational initiatives for von Willebrand Disease (VWD), the most common inherited bleeding disorder, at the 62nd Annual Meeting of the National Hemophilia Foundation (NHF) scheduled for Nov. 11-13 in...

Hemophilia A Clinical Trial Starts: First Recombinant Factor VIII Derived from a Human Cell-Line

Published: Nov 1, 2010 | Last modified: Nov 1, 2010
HOBOKEN, N.J. (November 1, 2010) - Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study...

Octapharma USA Accepting Applications for Research Grants Focused on Human Protein Therapies

Published: Oct 27, 2010 | Last modified: Oct 27, 2010
HOBOKEN, NJ (October 27, 2010) - Octapharma USA is accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immune therapy...
© Yankee Public Relations 2017 - powered by EggZack